However, AML NPM1mut offers several advantages over AML NPMWT, by virtue of their predominance of CD33+ diseased cells and an absence of CD34+, suggesting that the target population is not the more difficult to treat CD34+ LSC cells. This evidence concerns the gene CD33 and acute myeloid leukemia.